AbbVie (NYSE: ABBV) today announced that the European Commission has approved SKYRIZI® (risankizumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.3
Pharmaceutical giant AbbVie (ABBV) is getting a stock boost after the company's second quarter results topped Wall Street estimates. Yahoo Finance senior health reporter Anjalee Khemlani breaks down the earnings and how the pharmaceutical company responds to increased competition for its rheumatoid arthritis drug Humira. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2024.